On January 21, 2021 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, reported that the Company will present at the MoneyShow Accredited Investors Virtual Expo taking place virtually January 26-28, 2021 (Press release, Genprex, JAN 21, 2021, View Source [SID1234574169]). Genprex’s President and Chief Executive Officer, Rodney Varner, will virtually deliver a company overview, including recent progress made on its upcoming clinical trials, to participating investors on Thursday, January 28.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: MoneyShow Accredited Investors Virtual Expo

Presentation Date: Thursday, January 28

Presentation Time: 12:25 p.m. EST

Registration Link: http://bit.ly/3p0yJOl

The presentation will be available for replay on the Company’s website (www.genprex.com) for a period of time following the conference, and the video will be archived on MoneyShow.com.

On January 21, 2021 Prescient Therapeutics (ASX:PTX) reported that what’s next for its next-generation gene therapy technology for fighting cancer (Press release, Prescient Therapeutics, JAN 21, 2021, View Source;utm_medium=rss&utm_campaign=prescient-therapeutics-chooses-three-cancer-programs-for-its-next-generation-car-t-platform [SID1234574167]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Melbourne-based Prescient will focus development of its OmniCAR platform into three programs: the blood cancer acute myeloid leukemia (AML); solid tumours including breast, ovarian and gastric cancers; and glioblastoma multiforme, the aggressive brain cancer.

Prescient’s OmniCAR technology represents a step up from the current chimeric antigen receptor T-cell (CAR T) therapy, a form of immunotherapy that involves modifying a patient’s white blood cells so they recognise and kill cancer cells.

An American woman, Laurie Adami, recently told Stockhead how CAR T therapy saved her life by curing her stage IV follicular non-Hodgkin lymphoma.

Prescient says its OmniCAR tech is expected to be safer and more effective than the current generation of CAR T treatments, which are only a few years old.

CAR T cells using OmniCAR will be able to target multiple cancer antigens simultaneously, and the platform offers "persistent dosing and tumour microenvironment enhancements to improve efficacy," Prescient says.

While OmniCAR has a range of applications, the company decided to narrow its focus to the three cancer programs after a strategic review that took into account all the known CAR T programs in development worldwide.

The company said it tried to strike a balance between the probability of technical success and being able to bring to market a differentiated, commercially viable treatment. Prescient didn’t want to risk developing a "me too" CAR T treatment that duplicated an existing therapy.

"Each of the programs represent a tremendous market opportunity," says Prescient chief executive Steven Yatomi-Clarke.

"Furthermore, Prescient will continue to seek collaboration with external parties on additional opportunities where OmniCAR can create additional next-generation CAR therapies with partners."

Prescient licensed OmniCAR from the University of Pennsylvania, a leader in CAR T which developed Kymriah, a Novartis therapy approved as a treatment for B-cell acute lymphoblastic leukemia (ALL).

Prescient says the vigorous development program will move OmniCAR towards the clinic while demonstrating the unique features of the technology in treating patients – adding tremendous value to the platform.

On January 21, 2021 Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, reported that Snehal Patel, CEO of Greenwich LifeSciences, will participate in the following upcoming virtual investor conferences, highlighting the Company’s GP2 Phase IIb trial data and the planned Phase III trial (Press release, Greenwich LifeSciences, JAN 21, 2021, View Source [SID1234574165]). In addition, a video of the Company’s corporate presentation with comments by Snehal Patel will be available on the investor section of the Company’s website here.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

B. Riley Securities Oncology Investor Conference:

The Company will present at the virtual B. Riley Securities Oncology Investor Conference today, January 21, 2021 at approximately 11:30am EST and will participate in a question and answer session. The presentation will be live and available to conference attendees.

BIO CEO & Investor Conference:

The Company will present at the virtual 2021 BIO CEO & Investor Conference to be held from February 16-18, 2021 and will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. The presentation will include a pre-recorded audio track available to conference attendees on demand.

For more than 20 years, the BIO CEO & Investor Conference has fueled biotech industry networking with premier investor and banking communities, focused on established and emerging publicly traded and select private biotech companies. The virtual 2021 event, taking place February 16-18, will showcase the Biotechnology Innovation Organization’s (BIO) perspective on the new U.S. Congressional agenda, the record setting pace of biotech IPOs, and the hottest clinical developments and industry catalysts. In addition, there will be three days of BIO One-on-One Partnering meetings with institutional investors, industry analysts, and senior business development executives seeking potential investments and deal partners.

About Breast Cancer and HER2/neu Positivity

One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 266,000 new breast cancer patients and 3.1 million breast cancer survivors in 2018. HER2/neu (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels.

On January 21, 2021 Bristol Myers Squibb (NYSE:BMY) reported that it has changed the timing of its previously announced earnings conference call (Press release, Bristol-Myers Squibb, JAN 21, 2021, View Source [SID1234574162]). The Company will now host a conference call to discuss results for the fourth quarter of 2020 on Thursday, February 4, 2021 at 10 a.m. ET. During the call, company executives will review financial results and address inquiries from investors and analysts.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors and the general public are invited to listen to a live webcast of the call at View Source or by dialing in the U.S. toll free 800-458-4121 or international +1 313-209-6672, confirmation code: 4441406, or using this link which becomes active fifteen minutes prior to the scheduled start time and entering your information to be connected. Materials related to the call will be available at the same website prior to the conference call. A replay of the call will be available beginning at 1:30 p.m. ET on February 4 through 1:30 p.m. ET on February 18, 2021. The replay will also be available through View Source or by dialing in the U.S. toll free 888-203-1112 or international 719-457-0820, confirmation code: 4441406.

On January 20, 2021 ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. reported that the first Fc fusion protein drug targeting human CD47 (Project No.: IMM01) in China, expanding new indications (AML and MDS) and obtaining NMPA clinical trial research license (Press release, ImmuneOnco Biopharma, JAN 20, 2021, View Source [SID1234655623]). This is another milestone of ImmuneOnco’s further research and development of CD47 target drugs, and further establishes ImmuneOnco’s leading echelon position in the research and development of CD47 target drugs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are very glad to see that our IMM01 project has obtained the NMPA clinical trial research license to expand new indications. The phase I clinical trial of IMM01 project for lymphoma (HL & NHL) is coming to an end, and has obtained exciting clinical manifestations! We think that this is due to the difference design of IMM01 itself. IMM01 does not bind to human red blood cells at all. It avoids "antigenic sink" and does not appear ADA. It has small molecule (half of antibody). It has good tissue permeability and bioavailability. Therefore, we believe that IMM01 will have great advantages in clinical development. " Dr. Tian Wenzhi, founder and chairman of ImmuneOnco, is full of confidence in the clinical trial of IMM01. "We hope to further expand the research on new indications and combination drugs of IMM01 project in the future, so as to benefit more subjects. We will accelerate the clinical trial research of IMM01 and accelerate the listing of IMM01, so as to benefit cancer patients as soon as possible."